Skip to main content
In stock | Targeted Therapy (Investigational)

Rigosertib

Oncology Type Both (Solid & Hematologic)
Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
No Image
Description

Rigosertib is classified as a Polo-Like / Aurora Kinase Inhibitor, sourced for use within our Targeted Therapy (Investigational) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy (Investigational)
Oncology Type Both (Solid & Hematologic)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3